Chronic rhinosinusitis with nasal polyps - Epidemiology Forecast - 2034

Key Highlights

• As per the analysis CRSwNP accounted for approximately 4,381 thousand cases in the 7MM in 2022.
• The analyst projects that among the total diagnosed prevalent cases of CRSwNP in 7MM approximately 50% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 1,987 thousand diagnosed prevalent cases of CRSwNP.
• According to the analysis conducted by the publisher, CRSwNP was diagnosed in approximately 43% of females and 57% of males within the 7MM in 2022. This analysis indicates a higher prevalence of CRSwNP among males than females.

The “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Epidemiology - 2034” report delivers an in-depth understanding of the CRSwNP, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Diagnosis Algorithm

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Overview

CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, and cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are more prone to get nasal polyps.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Diagnosis

CRSwNP presents diagnostic challenges, which are particularly relevant in the elderly population. The diagnosis of CRSwNP requires the presence of bilateral, endoscopically visualized polyps in the middle meatus. However, in the absence of polyps, patients may still experience symptoms of CRSwNP, leading to potential misdiagnosis or underdiagnosis. The elderly population may be more susceptible to the negative impacts of CRSwNP, as they tend to have poorer health outcomes compared to younger patients.

Biomarkers have shown promise in the diagnosis and prognosis of CRSwNP, particularly periostin levels, which have been found to identify patients with CRSwNP.

To address these challenges, a multidisciplinary approach is necessary, involving specialists such as allergists and ENTs in the diagnosis of CRSwNP.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Epidemiology

As the market is derived using the patient-based model, the CRSwNP epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of CRS, Diagnosed Prevalent Cases of CRS, Diagnosed Prevalent cases of CRSwNP, and Gender-specific Diagnosed Prevalent cases of CRSwNP in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per the estimations, the total prevalent cases of CRS (Chronic Rhinosinusitis) in the 7MM were approximately 69,872 thousand cases in 2022 and are projected to increase during the forecast period.

• There were approximately 18,063 thousand diagnosed cases of Chronic Rhinosinusitis (CRS), which accounts for roughly 26% of the total prevalent cases of CRS in the 7MM, in 2022. This suggests that a significant portion of individuals with CRS have received a formal diagnosis, indicating the recognition and awareness of this condition within the population.
• The overall count of individuals diagnosed with CRSwNP in the United States was nearly 2,191 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034). The anticipated surge in CRSwNP cases in the US stems from a combination of aging demographics, environmental stressors, lifestyle shifts, heightened diagnostic acumen, and the interplay of allergic and inflammatory factors.
• Among the 7MM, EU4 and the UK accounted for approx. 1,987 thousand diagnosed prevalent cases of CRSwNP, and these cases are expected to increase during the forecast period (2023-2034). However, the diagnosed prevalent cases of CRSwNP are expected to decrease in Germany attributed to decrease in country population and other factors.
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of CRSwNP, with around 617 thousand cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were nearly 202 thousand diagnosed prevalent cases of CRSwNP in 2022. These cases are expected to decrease at a significant CAGR throughout the study period (2023-2034) attributed to decrease in country population, advancements in healthcare, heightened awareness, stringent environmental regulations, and culturally ingrained preventive measures fostering nasal health and hygiene practices.
• Gender-specific diagnosed prevalent cases of CRSwNP showed that males (60%) were more affected by CRSwNP than females (40%) in the EU4 and the UK in 2022. This gender disparity is expected to stem from hormonal, genetic, and anatomical differences, as well as varied immune responses, lifestyle factors, and occupational exposures influencing nasal inflammation and susceptibility to sinusitis.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on CRSwNP including KOL from Wright State University Boonshoft School of Medicine, Fairborn, US; University of Pennsylvania, Perelman School of Medicine, Philadelphia; University of Siena, Italy; University of Southampton, Southampton, UK; University of Fukui, Fukui, Japan, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of CRSwNP, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

CRSwNP Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Prevalence of CRS
• Diagnosed Prevalence of CRS
• Diagnosed Prevalence of CRSwNP
• Gender-specific Diagnosed Prevalence of CRSwNP

CRSwNP Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• CRSwNP Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of CRSwNP? What will be the growth opportunities across the 7MM concerning the patient population of CRSwNP?
• What is the historical and forecasted CRSwNP patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for CRSwNP and why?
• What factors are affecting the diagnosis of CRSwNP?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the CRSwNP diagnosed prevalent cases in varying geographies over the coming years.
• A detailed overview of diagnosed and Gender-specific diagnosed prevalence of CRSwNP.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The CRSwNP Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of CRSwNP cases in 2022?
The highest cases of CRSwNP was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of CRSwNP cases in 2022?

The highest cases of CRSwNP were found in the US among the 7MM in 2022.